0354 GMT - ResMed's exemption from U.S. tariffs supports the breath-tech provider's already strong competitive position, according to Morgans analyst Derek Jellinek. He tells clients in a note that the exemption is important, but that he already liked ResMed for its expanding U.S. manufacturing footprint, the emergence of new technologies driving adoption, and favorable trends in wearables and weight-loss drugs. Jellinek observes that growth in ResMed's U.S. mask sales continues to outpace that of the broader industry, with rest-of-world sales growth poised to eventually catch up. Morgans keeps an add rating on the stock and raises its target price 1.1% to A$44.07. Shares are up 2.6% at A$37.005.(stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 27, 2025 23:54 ET (03:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。